The Influence of Previous Antipsychotic Polypharmacy Versus Monotherapy on the Effectiveness of Antipsychotic after Switching to Paliperidone Extended-release
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Although antipsychotic polypharmacy is widely used in the pharmacotherapy of schizophrenia, its effectiveness is controversial. In particular, clinicians tend to avoid switching to monotherapy in patients who have been prescribed polypharmacy. In the present study, the authors investigate whether there is difference in time to discontinuation of antipsychotics between patients on previous monotherapy or polypharmacy. Methods: Pooled analysis was conducted on two 24-week, multicenter, open-label, non-comparative studies that were originally designed to investigate the effectiveness of switching to paliperidone extended-release (ER) in patients with schizophrenia. Patients were divided into two groups according to previously prescribed antipsychotics, that is, to a polypharmacy group or a monotherapy group. The primary outcome measure was time to discontinuation of paliperidone ER. In addition, the authors sought to identify clinical variables that influence time to discontinuation. Results: Before switching to paliperidone ER, 535 of 673 (79.5%) patients were prescribed antipsychotic monotherapy, and the remaining 138 (20.5%) patients were prescribed antipsychotic polypharmacy. No significant differences in time to discontinuation of paliperidone ER were observed between the polypharmacy and monotherapy groups. Personal and social performance scale score was the only factor found to influence time to discontinuation of paliperidone ER. No differences in psychopathology or adverse effects were found between the monotherapy and polypharmacy groups. Conclusion: Our results suggest that number of antipsychotics prescribed before switching to monotherapy does not influence clinical prognosis in patients with schizophrenia.
Abstract
Objective: Although antipsychotic polypharmacy is widely used in the pharmacotherapy of schizophrenia, its effectiveness is controversial. In particular, clinicians tend to avoid switching to monotherapy in patients who have been prescribed polypharmacy. In the present study, the authors investigate whether there is difference in time to discontinuation of antipsychotics between patients on previous monotherapy or polypharmacy. Methods: Pooled analysis was conducted on two 24-week, multicenter, open-label, non-comparative studies that were originally designed to investigate the effectiveness of switching to paliperidone extended-release (ER) in patients with schizophrenia. Patients were divided into two groups according to previously prescribed antipsychotics, that is, to a polypharmacy group or a monotherapy group. The primary outcome measure was time to discontinuation of paliperidone ER. In addition, the authors sought to identify clinical variables that influence time to discontinuation. Results: Before switching to paliperidone ER, 535 of 673 (79.5%) patients were prescribed antipsychotic monotherapy, and the remaining 138 (20.5%) patients were prescribed antipsychotic polypharmacy. No significant differences in time to discontinuation of paliperidone ER were observed between the polypharmacy and monotherapy groups. Personal and social performance scale score was the only factor found to influence time to discontinuation of paliperidone ER. No differences in psychopathology or adverse effects were found between the monotherapy and polypharmacy groups. Conclusion: Our results suggest that number of antipsychotics prescribed before switching to monotherapy does not influence clinical prognosis in patients with schizophrenia.
참고문헌 (22)
- American Psychiatric Association; American Psychiatric Association., "Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders" (2000), American Psychiatric Association
- Buchanan RW, "Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements", Schizophr Bull, 36, pp.71~93 (2010)
- Treatment of schizophrenia 1999, "The expert consensus guideline series", J Clin Psychiatry, 60(Suppl 11), pp.3~80 (1999)
- Lehman AF, "American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition", Am J Psychiatry, 161(2 Suppl), pp.1~56 (2004)
- Miller A, "The texas medication algorithm project antipsychotic algorithm for schizophrenia: 2003 update", J Clin Psychiatry, 65, pp.500~508 (2004)
- Essock SM, "Effectiveness of switching antipsychotic medications", Am J Psychiatry, 163, pp.2090~2095 (2006)
- Tapp A, "Combination antipsychotic therapy in clinical practice", Psychiatr Serv, 54, pp.55~59 (2003)
- Sernyak MJ, "Clinicians' reasons for antipsychotic coprescribing", J Clin Psychiatry, 65, pp.1597~1600 (2004)
- Suzuki T, "Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia", Int J Neuropsychopharmacol, 7, pp.133~142 (2004)
- Essock SM, "Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy", Am J Psychiatry, 168, pp.702~708 (2011)
- Tsutsumi C, "The evolution of antipsychotic switch and polypharmacy in natural practice-a longitudinal perspective", Schizophr Res, 130, pp.40~46 (2011)
- Krawiecka M, "A standardized psychiatric assessment scale for rating chronic psychotic patients", Acta Psychiatr Scand, 55, pp.299~308 (1977)
- Morosini PL, "Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning", Acta Psychiatr Scand, 101, pp.323~329 (2000)
- Stroup TS, "Schizophrenia Trials Network. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)", Am J Psychiatry, 168, pp.947~956 (2011)
- Essock SM, "Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in new york state", Psychiatr Serv, 60, pp.1595~1602 (2009)
- Waddington JL, "Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study", Br J Psychiatry, 173, pp.325~329 (1998)
- Correll CU, "Does antipsychotic polypharmacy increase the risk for metabolic syndrome?", Schizophr Res, 89, pp.91~100 (2007)
- Joukamaa M, "Schizophrenia, neuroleptic medication and mortality", Br J Psychiatry, 188, pp.122~127 (2006)
- Kane J, "Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial", Schizophr Res, 90, pp.147~161 (2007)
- Emsley R, "Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies", Int Clin Psychopharmacol, 23, pp.343~356 (2008)
- Canuso CM, "Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone", Int Clin Psychopharmacol, 23, pp.209~215 (2008)
- Marder SR, "Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study", Biol Psychiatry, 62, pp.1363~1370 (2007)